BlackRock’s AbbVie ABBV Stock Holding History

BlackRock’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-51,500	Closed	-$11.2M	–	5695
2026 Q1	$11.2M	Buy	+51,500	New	+$11.4M	﹤0.01%	3427
2016 Q4	–	Sell	-1,500	Closed	-$95K	–	3723
2016 Q3	$95K	Buy	+1,500	New	+$97.1K	﹤0.01%	2621

Other funds holding ABBV

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock's ABBV Position: Q2 2026 in Review

BlackRock reduced its AbbVie (ABBV) stake by 0.8% in Q2 2026, selling an estimated $260M and leaving 149,488,412 shares worth $37.6B. The position accounts for 0.56% of the portfolio, ranked #26.

BlackRock first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

BlackRock held 149,488,412 shares of AbbVie worth $37.6B as of Q2 2026.
BlackRock sold 1,209,713 AbbVie shares in Q2 2026, an estimated $260M.
AbbVie made up 0.56% of BlackRock's portfolio in Q2 2026, its #26 holding.
BlackRock first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.